In partnership with
The EverLife Capital Brief · November 3, 2026
For investors curious about private deals: Alternative Investing Report is a free morning email on private-market investing, from venture and real estate to art and collectibles, read by more than 95,000 people. If the private longevity companies in these issues interest you, it shows how everyday investors get access to deals outside the stock market. Try Alternative Investing Report free →
Paid links: EverLife Capital earns a referral fee if you subscribe (one click), and is paid per click on sponsor messages. I only include things I believe can help you.
Today in 3 minutes:
A personal note: I've used OneSkin for a long time and still like it. Here's their message.
Why Your Moisturizer Stops Working
If your moisturizer isn’t working quite like it used to, you’re not alone. As we age, our skin shifts below the surface—losing the collagen, elastin, hyaluronic acid, and barrier integrity it needs to stay hydrated and firm. This leads to thinner, weaker skin that struggles to retain moisture, no matter how many “hydrating” creams you apply.
But OneSkin’s new OS-01 FACE RICH CREAM is built differently. While most moisturizers sit on the skin’s surface and wash off at the end of the day, OS-01 FACE RICH CREAM works at the cellular level to actually rebuild the density that allows skin to hold onto moisture. It’s powered by a Dual-Phase Hydration System, combining potent bioactive humectants with OneSkin’s age-reversing OS-01 Peptide™ to promote healthier collagen, elastin, and hyaluronic acid production, and fortify the skin barrier. The results: deep, lasting hydration and progressive visible firmness—for resilient skin that keeps up with you.
Human Result: The Frailest Patients Did Better, Not Worse
Shown in: people, more than 17,000 adults (average age about 62) with heart disease and excess weight. Stage: approved drug, new analysis.
Doctors often hold back strong drugs from frail older patients. A new look at the SELECT trial found semaglutide (the drug in Wegovy and Ozempic) lowered heart attacks, strokes and heart deaths at every frailty level. Frailer patients were more likely to see their frailty score improve, and less likely to stop the drug because of side effects.
The catch: this was an after-the-fact analysis, and it does not show the drug restores strength.
Company: Novo Nordisk (NVO), public. $40.45 per US share at the Nov 2 close, market value about $176 billion, cash about $6.9 billion (latest reported quarter).
Why it matters: frailty is aging you can see. A drug that helps the frail instead of hurting them is aimed at one of aging's hardest outcomes.
Source: JAMA, Oct 30, 2026, on a secondary analysis of the SELECT trial in JAMA Cardiology
Keeping Muscle On Weight-Loss Drugs: One Dose, In Monkeys
Shown in: monkeys (obese, 6 per group, 8 weeks). Stage: lab; the first human study is planned for the first half of 2027.
Weight-loss shots take off muscle along with fat, and lost muscle is what makes older people frail. iBio gave monkeys on semaglutide a single dose of its antibody IBIO-610, which blocks a signal called Activin E. In that group, 93% of the weight lost was fat, versus 77% with semaglutide alone. iBio says the drug lasted long enough in monkeys that people might someday need it only twice a year.
The catch: six monkeys per group, and no human data yet.
Company: iBio (IBIO), public. $0.80 per share at the Nov 2 close, market value about $51 million, cash and short-term investments about $88 million (June 30, 2026). The shares trade under $1, which can lead to Nasdaq listing problems.
Why it matters: if it works in people, older adults could lose weight without losing the strength they need to stay independent.
Source: Longevity.Technology, Oct 29, 2026, on iBio primate data
For keeping your own strength: Wits & Weights is a free newsletter on evidence-based strength training and nutrition for busy people over 40 who want to build muscle and lose fat without crash diets. Try Wits & Weights free →
EverLife Capital Members
Look Beyond The Breakthrough Headlines
Members get plain-English analysis of each company we cover: who the results were shown in, and the warning signs to check before putting money in. You can also ask us to analyze the companies you care about. Free for 14 days.
Biotechnology investments can lose substantial value, including your entire investment. Clinical success or regulatory approval does not guarantee commercial success or investment returns.
Hype Check: A Zombie-Cell Vaccine Added 12% To Lifespan
Shown in: mice (10 per group). Stage: lab only, no company attached.
Scientists in China trained the immune systems of mice to hunt senescent "zombie" cells, the worn-out cells that pile up with age. Old female mice vaccinated at 75 weeks lived 12% longer on average, and their fat and blood-sugar markers improved.
Before you get excited: only 10 mice per group, the untreated mice died young for their strain (which can make any treatment look better), and the authors call it a proof of concept. Worth watching, not counting on yet.
Source: Advanced Science, 2026, via Lifespan.io
Do This Now: The Hearing-Aid Finding Most People Get Wrong
Shown in: people (the ACHIEVE trial, published in The Lancet in 2023).
Over three years, hearing aids made no difference to memory decline for most people in the trial. But in the group already at higher risk of dementia, decline was 48% slower.
If you or a parent keeps asking people to repeat themselves, a hearing test is cheap and may help protect the brain. Ask your doctor or an audiologist.
Source: Lin et al., The Lancet, 2023 (ACHIEVE)
For your morning market check: Market Briefing is a free pre-market email on the deals, downgrades and overnight news that move stocks before the open. Try Market Briefing free →
Which would you back first?
Saved For Last: A Kidney Kept At -150°C For A Year Still Worked
Shown in: pigs (human-sized kidneys). Stage: lab, in a preprint that is not yet peer-reviewed; no company named.
Researchers turned pig kidneys glass-like without ice crystals, stored them at -150°C for up to a year, rewarmed them with tiny iron particles heated by a magnetic field, and transplanted them. The kidneys filled with blood evenly and made urine right away, recovering nearly as well as kidneys kept on ice, the standard method today.
Why it matters: today a donated kidney can only wait outside the body for about a day or two. Banking organs for months could someday mean a matching organ waits for the patient, not the other way around. It is one path to replacing worn-out parts.
Source: preprint DOI 10.64898/2026.10.07.756990, via Fight Aging!, Oct 26, 2026
Want to advertise in EverLife Capital? Reach readers focused on aging well and longevity science. Email [email protected]. We do not accept payment, directly or through agencies, from companies we cover.
EverLife Capital publishes general educational research, not personalized investment or medical advice, and nothing here is a recommendation to buy or sell any security. EverLife Capital earns referral fees when readers subscribe to Alternative Investing Report, Wits & Weights or Market Briefing through this issue, and is paid per click on sponsor messages; no company covered in this issue paid for coverage, directly or indirectly. Early clinical findings and animal results may not lead to lasting benefits for patients, and clinical progress does not guarantee investment returns. Treatment decisions belong with a qualified clinician. Prices are dated where shown and may have changed. EverLife Capital is published by Consult US, LLC. Neither Eric Pemper nor Consult US, LLC holds positions in companies mentioned. Some research and summaries are prepared with AI assistance and reviewed before publication.
